NCT02561091View on ClinicalTrials.gov

AM-111 in the Treatment of Acute Inner Ear Hearing Loss

PHASE3CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Hearing Loss
Interventions
OTHER

Placebo

DRUG

AM-111 0.4 mg/ml

DRUG

AM-111 0.8 mg/ml

Trial Locations (1)

Unknown

Please check link to study webpage below for more study sites, Sofia

Sponsors

Lead Sponsor

Auris Medical AG
All Listed Sponsors
lead

Auris Medical AG

INDUSTRY

NCT02561091 - AM-111 in the Treatment of Acute Inner Ear Hearing Loss | Biotech Hunter | Biotech Hunter